Bristol-Myers Slips Suit Over $6.4B Investor Payment, For Now

By Lauren Berg · March 1, 2023, 10:43 PM EST

A Manhattan federal judge Wednesday dismissed a proposed class action alleging Bristol-Myers Squibb Co. and its executives intentionally delayed the U.S. Food and Drug Administration's approval of a cancer treatment developed...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

SM Merger/Arbitrage, L.P. et al v. Bristol-Myers Squibb Company et al

Case Number

1:21-cv-08255

Court

New York Southern

Nature of Suit

Securities/Commodities

Date Filed

October 06, 2021